NAPOLITANO, Stefania
 Distribuzione geografica
Continente #
EU - Europa 1.378
NA - Nord America 1.145
AS - Asia 103
AF - Africa 1
OC - Oceania 1
SA - Sud America 1
Totale 2.629
Nazione #
US - Stati Uniti d'America 1.124
IE - Irlanda 592
IT - Italia 316
DE - Germania 132
GB - Regno Unito 100
UA - Ucraina 65
CN - Cina 61
FR - Francia 49
SE - Svezia 40
GR - Grecia 31
FI - Finlandia 23
CA - Canada 19
TR - Turchia 15
BE - Belgio 12
PK - Pakistan 8
IN - India 6
VN - Vietnam 6
NL - Olanda 4
AT - Austria 3
ES - Italia 3
MK - Macedonia 3
CZ - Repubblica Ceca 2
GI - Gibilterra 2
IR - Iran 2
MX - Messico 2
SG - Singapore 2
AR - Argentina 1
AU - Australia 1
BW - Botswana 1
HK - Hong Kong 1
HU - Ungheria 1
JP - Giappone 1
LK - Sri Lanka 1
Totale 2.629
Città #
Dublin 578
Chandler 282
Jacksonville 108
New York 72
Bremen 68
Princeton 66
Roxbury 66
Naples 60
Caserta 39
Cambridge 37
Beijing 36
Ann Arbor 33
Medford 29
Wilmington 20
Elora 16
Ashburn 15
Des Moines 14
Napoli 13
Brussels 12
Woodbridge 12
Boardman 11
Lappeenranta 10
Houston 9
Munich 9
San Mateo 9
Rome 8
Dong Ket 6
Jinan 6
Los Angeles 6
Nanjing 6
Battipaglia 5
Düsseldorf 5
Menlo Park 5
Milan 5
Mountain View 5
Pozzuoli 5
Ercolano 4
Fairfield 4
Auburn Hills 3
Colle di Val d'Elsa 3
Helsinki 3
Madrid 3
Montecorvino Rovella 3
Nanchang 3
Norwalk 3
Sennori 3
Toronto 3
Venice 3
Viareggio 3
Vienna 3
Acerra 2
Alba Adriatica 2
Amsterdam 2
Anantapur 2
Andover 2
Avellino 2
Berlin 2
Brno 2
Castellammare di Stabia 2
Cinquevie 2
Corbara 2
Florence 2
Groningen 2
Gunzenhausen 2
Matera 2
Mexico 2
Molinella 2
Nola 2
Pune 2
San Nicola la Strada 2
Seattle 2
Shenyang 2
Skopje 2
Strasbourg 2
Antea 1
Bari 1
Bedizzole 1
Benevento 1
Bezons 1
Castellammare Di Stabia 1
Catania 1
Central 1
Cercola 1
Falconara Marittima 1
Formello 1
Gaborone 1
Genova 1
Hangzhou 1
Hebei 1
Hyderabad 1
Jiaxing 1
Kunming 1
L'aquila 1
London 1
Lviv 1
Maharagama 1
Marcianise 1
Marigliano 1
Miami 1
Monmouth Junction 1
Totale 1.804
Nome #
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 92
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 85
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 78
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 78
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 68
AXL is an oncotarget in human colorectal cancer 61
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? 60
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 57
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 56
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 56
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 55
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 50
MET ACTIVATION BY AUTOCRINE LOOP RESCUES COLON CANCER CELLS FROM SENSITIVITY TO EGFR INHIBITION 50
It is finally time for adjuvant therapy in melanoma 48
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 46
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 46
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 44
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 44
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 43
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 43
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 42
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 42
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 41
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 39
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 38
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines 38
PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples 38
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 36
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations 36
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 36
Treatment of cutaneous melanoma harboring smo p.Gln216arg mutation with imiquimod: An old drug with new results 35
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation 34
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 34
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 34
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 34
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 34
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 34
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 33
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 32
Novel in vitro cancer models for optimizing anti- EGFR therapies 32
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 32
Immunotherapy for head and neck cancer: Present and future 32
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 32
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 31
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 31
Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma 31
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression 29
Skin toxicity as predictor of survival in refractory patients with ras wild‐type metastatic colorectal cancer treated with cetuximab and avelumab (Cave) as rechallenge strategy 29
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 28
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models 27
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 27
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 26
Feasibility of next-generation sequencing in clinical practice: Results of a pilot study in the Department of Precision Medicine at the University of Campania ' Luigi Vanvitelli' 26
Clinical management of metastatic colorectal cancer in the era of precision medicine 26
Pimasertib hydrochloride 25
Beyond N staging in colorectal cancer: Current approaches and future perspectives 24
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? 23
Anti-EGFR-resistant clones decay exponentially after progression: Implications for anti-EGFR re-challenge 23
Current Landscape and Open Questions on Adjuvant Therapies in Melanoma 23
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 21
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 21
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 20
Predictive Evaluation on Cytological Sample of Metastatic Melanoma: The Role of BRAF Immunocytochemistry in the Molecular Era 20
Towards the era of precision medicine in metastatic colorectal cancer 19
How we treat metastatic colorectal cancer 19
NMR profiling of Ononis diffusa identifies cytotoxic compounds against cetuximab-resistant colon cancer cell lines 18
Hypothalamic–pituitary autoimmunity in patients treated with anti-pd-1 and anti-pd-l1 antibodies 18
Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer 18
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 17
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC 16
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data 16
Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941 16
Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. 15
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 13
Optimization of the Development of Old and New EGFR and MAP Kinase Inhibitors for Colorectal Cancer 13
Mechanisms of innate and acquired resistance to anti-EGFR therapy: A review of current knowledge with a focus on rechallenge therapies 13
Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment 12
The Role of Sentinel Node Biopsy in the Era of Adjuvant Therapy for Melanoma 12
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 11
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial 11
How can we manage the cardiac toxicity of immune checkpoint inhibitors? 11
"RT STRIKES BACK": Radiotherapy in Ultra Elderly with Cutaneous Basal Cell Carcinoma 10
Post-Irradiation Breast Angiosarcoma: All the Possible Treatments and Electrochemotherapy. Case Report and Literature Review 9
Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy 6
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 6
Sentinel node biopsy in thin melanoma: a retrospective descriptive cohort study 5
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 5
The Role of Adjuvant Therapy for the Treatment of Micrometastases in Endometrial Cancer: A Systematic Review and Meta-Analysis 4
MicroRNA Expression in Endometrial Cancer: Current Knowledge and Therapeutic Implications 1
Magnetic Resonance Imaging Evaluation of Bone Metastases Treated with Radiotherapy in Palliative Intent: A Multicenter Prospective Study on Clinical and Instrumental Evaluation Assessment Concordance (MARTE Study) 1
Totale 2.804
Categoria #
all - tutte 12.935
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.935


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201917 0 0 0 0 0 0 0 0 0 0 14 3
2019/2020206 30 21 11 9 16 6 34 10 27 26 12 4
2020/2021256 28 11 18 20 23 13 25 23 12 29 38 16
2021/2022514 15 13 6 4 105 15 38 15 30 59 64 150
2022/20231.193 127 18 32 96 149 97 5 66 545 9 33 16
2023/2024462 61 25 17 23 158 88 18 22 18 14 18 0
Totale 2.804